Related Experiment Video
Updated: Nov 10, 2025
09:36
Halogenated Agent Delivery in Porcine Model of Acute Respiratory Distress Syndrome via an Intensive Care Unit Type Device
Published on: September 24, 2020
2.9K
Drugs intervention study in COVID-19 management.
Muhammad Taher1, Noratika Tik1, Deny Susanti2
1Faculty of Pharmacy, International Islamic University Malaysia, Kuantan, Pahang, Malaysia.
Drug Metabolism and Personalized Therapy
|April 5, 2021
Summary
This review identifies effective COVID-19 treatments. Remdesivir, ivermectin, hydroxychloroquine, favipiravir, corticosteroids, and convalescent plasma show therapeutic benefits for Coronavirus 2019 management.
Area of Science:
- Infectious Diseases
- Pharmacology
- Critical Care Medicine
Background:
- The Coronavirus (COVID-19) pandemic caused significant global mortality by February 2021.
- Effective therapeutic interventions are crucial for managing COVID-19 and mitigating its impact.
Purpose of the Study:
- To systematically review and identify potential therapeutic approaches and drugs for Coronavirus 2019 (COVID-19) management.
- To evaluate the clinical evidence supporting various treatment options for COVID-19.
Main Methods:
- A systematic scoping review of articles reporting clinical evidence for COVID-19 therapeutic management.
- Searches were conducted across Google Scholar, PubMed, and Science Direct databases.
- 31 articles were selected based on predefined inclusion and exclusion criteria.
Main Results:
- Remdesivir and ivermectin demonstrated significant reduction in viral ribonucleic acid (RNA) activity.
- Convalescent plasma (CP) significantly improved clinical symptoms in COVID-19 patients.
- Corticosteroids increased survival rates in patients with acute respiratory distress syndrome (ARDS).
- Hydroxychloroquine and favipiravir showed effectiveness against SARS-CoV-2.
- Lopinavir-ritonavir combination was found ineffective.
- Ribavirin, galidesivir, and sofosbuvir showed potential but lacked robust clinical evidence.
Conclusions:
- Remdesivir, ivermectin, favipiravir, hydroxychloroquine, dexamethasone, methylprednisolone, and convalescent plasma are identified as potentially valuable therapeutic agents for COVID-19 management.
- Further clinical evidence is needed for agents like ribavirin, galidesivir, and sofosbuvir.
- The findings provide insights into current therapeutic strategies for COVID-19.
Related Concept Videos
01:28Acute Coronary Syndrome IV: Interprofessional Care
75
IntroductionThe management of Acute Coronary Syndrome (ACS) aims to minimize myocardial damage, preserve myocardial function, and prevent complications.Initial ManagementInpatient management involves continuous cardiac monitoring, preferably in an ICU, focusing on blood pressure, serum sodium, potassium, and creatinine levels, and urine output. Ongoing pharmacologic management is crucial for stabilizing the patient.Supplemental Oxygen: Administer supplemental oxygen if oxygen saturation is...
75
01:13Controls in Experiments
14.3K
When conducting an experiment, it is crucial to have control to reduce bias and accurately measure the dependent variables. It also marks the results more reliable. Controls are elements in an experiment that have the same characteristics as the treatment groups but are not affected by the independent variable. By sorting these data into control and experimental conditions, the relationship between the dependent and independent variables can be drawn. A randomized experiment always includes a...
14.3K
01:29Therapeutic Drug Monitoring: Affecting Factors
55
Therapeutic Drug Monitoring (TDM) is the clinical practice of measuring specific drug levels in a patient's blood or body tissues to manage and optimize therapy. TDM is crucial for drugs with narrow therapeutic windows, like warfarin and phenytoin, where incorrect doses can lead to treatment failure or severe side effects. This monitoring ensures the dosage administered is within a safe and effective range. The factors affecting therapeutic drug monitoring include:Patient-Specific Factors:a.
55
01:28Pneumonia IV: Management
554
The treatment of pneumonia varies based on its severity and the causative pathogen. Here is a structured approach to managing pneumonia, integrating pharmaceutical and supportive care strategies.
Bacterial Pneumonia Treatment
For bacterial pneumonia, antibiotics serve as the cornerstone of therapy. Initial treatment often begins with empirical antibiotics, tailored to the anticipated causative organism and adjusted based on culture results. Key antibiotic choices include:
Bacterial Pneumonia Treatment
For bacterial pneumonia, antibiotics serve as the cornerstone of therapy. Initial treatment often begins with empirical antibiotics, tailored to the anticipated causative organism and adjusted based on culture results. Key antibiotic choices include:
554
01:29Chronic Obstructive Pulmonary Disease-V: Management
2.8K
Managing Chronic Obstructive Pulmonary Disease (COPD) involves a multifaceted approach to reduce symptoms, prevent exacerbations, improve overall health status, and slow disease progression. Key strategies include lifestyle modifications, pharmacotherapy, supportive therapies, and, in some cases, surgery. Here is an overview of the primary COPD management strategies:
Smoking Cessation
Smoking Cessation
2.8K
01:28Antimicrobial Effectiveness
714
The effectiveness of antimicrobial agents depends on various factors influencing their ability to eliminate microbial populations. Larger microbial populations require more time for complete eradication, emphasizing the importance of population size analysis when evaluating antimicrobial efficacy.Microbial resistance to antimicrobial agents varies significantly. Highly resilient microorganisms include endospores, gram-negative bacteria, and non-enveloped viruses, while prions are exceptionally...
714